Key result
Empagliflozin use was associated with a significant increase in QRS duration among diabetes patients with heart failure.
Why the study?
Empagliflozin binds to late sodium channels in mice cardiomyocytes, prompting investigation of electrocardiographic features associated with its use in patients with diabetes mellitus.
Does empagliflozin alter electrocardiographic features in patients with diabetes mellitus?
Observational (n=101)
Does empagliflozin alter electrocardiographic features in patients with diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Empagliflozin initiation is associated with a significant increase in QRS duration in patients with diabetes and heart failure.
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes mellitus. We compared ECG features of 101 patients before and after initiation of empagliflozin and found that empagliflozin was associated with a significant increase in QRS duration among diabetes patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Antwi‐Amoabeng et al. (2022) conducted an observational in Diabetes mellitus (n=101). Empagliflozin vs. Before initiation of empagliflozin (baseline) was evaluated on Electrocardiographic (ECG) features, specifically QRS duration. Empagliflozin use was associated with a significant increase in QRS duration among diabetes patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: